These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 36187919)

  • 1. Targeting N6-methyladenosine RNA modification combined with immune checkpoint Inhibitors: A new approach for cancer therapy.
    Liu W; Liu C; Wang H; Xu L; Zhou J; Li S; Cheng Y; Zhou R; Zhao L
    Comput Struct Biotechnol J; 2022; 20():5150-5161. PubMed ID: 36187919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roles and therapeutic implications of m6A modification in cancer immunotherapy.
    Pan J; Huang T; Deng Z; Zou C
    Front Immunol; 2023; 14():1132601. PubMed ID: 36960074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of m6A Epigenetic Modification in the Treatment of Colorectal Cancer Immune Checkpoint Inhibitors.
    Tong H; Wei H; Smith AO; Huang J
    Front Immunol; 2021; 12():802049. PubMed ID: 35069586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting RNA N6-methyladenosine to synergize with immune checkpoint therapy.
    Zhou X; Li C; Chen T; Li W; Wang X; Yang Q
    Mol Cancer; 2023 Feb; 22(1):36. PubMed ID: 36810108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of N6-methyladenosine RNA modification in cancer.
    Qu Y; Gao N; Zhang S; Gao L; He B; Wang C; Gong C; Shi Q; Li Z; Yang S; Xiao Y
    MedComm (2020); 2024 Sep; 5(9):e715. PubMed ID: 39252821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting RNA N
    Li W; Hao Y; Zhang X; Xu S; Pang D
    Mol Cancer; 2022 Sep; 21(1):176. PubMed ID: 36071523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The regulation of N6-methyladenosine modification in PD-L1-induced anti-tumor immunity.
    Yu W; Lin J; Yu T; Lou J; Qian C; Xu A; Liu B; Tao H; Jin L
    Immunol Cell Biol; 2023 Mar; 101(3):204-215. PubMed ID: 36630591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in crosstalk between N6-methyladenosine (m6A) modification and circular RNAs in cancer.
    Huang X; Guo H; Wang L; Yang L; Shao Z; Zhang W
    Mol Ther Nucleic Acids; 2022 Mar; 27():947-955. PubMed ID: 35211355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of N6-Methyladenosine RNA Methylation Regulators in Immune Infiltrates of Ovarian Cancer.
    Gu J; Bi F
    Front Genet; 2021; 12():671179. PubMed ID: 34306015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The emerging therapeutic target of dynamic and reversible N6-methyladenosine modification during cancer development.
    Liu S; Chen S; Tang C; Zhao Y; Cui W; Jia L; Wang L
    Front Oncol; 2022; 12():970833. PubMed ID: 36226062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Research advances of N6-methyladenosine in diagnosis and therapy of pancreatic cancer.
    Chen S; Ren H; Zhang X; Chang L; Wang Z; Wu H; Zhang J; Ren J; Zhou L
    J Clin Lab Anal; 2022 Sep; 36(9):e24611. PubMed ID: 35837987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RNA Modification of N6-Methyladenosine Predicts Immune Phenotypes and Therapeutic Opportunities in Kidney Renal Clear Cell Carcinoma.
    Li H; Hu J; Yu A; Othmane B; Guo T; Liu J; Cheng C; Chen J; Zu X
    Front Oncol; 2021; 11():642159. PubMed ID: 33816290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive analysis of tumor immune microenvironment and prognosis of m6A-related lncRNAs in gastric cancer.
    Wang Y; Zhu GQ; Tian D; Zhou CW; Li N; Feng Y; Zeng MS
    BMC Cancer; 2022 Mar; 22(1):316. PubMed ID: 35331183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive Analysis of N6-methyladenosine Modification Patterns Associated With Multiomic Characteristics of Bladder Cancer.
    Liu J; Wang J; Wu M; Zhang W; Meng L; Wang J; Lv Z; Xia H; Zhang Y; Wang J
    Front Med (Lausanne); 2021; 8():757432. PubMed ID: 35004726
    [No Abstract]   [Full Text] [Related]  

  • 15. m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in hepatocellular carcinoma.
    Huang X; Qiu Z; Li L; Chen B; Huang P
    Aging (Albany NY); 2021 Aug; 13(16):20698-20715. PubMed ID: 34461607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N6-methyladenosine Regulator-Mediated Immune Genes Identify Breast Cancer Immune Subtypes and Predict Immunotherapy Efficacy.
    Zhang MM; Lin YL; Zeng WF; Li Y; Yang Y; Liu M; Ye YJ; Jiang KW; Wang S; Wang S
    Front Genet; 2021; 12():790888. PubMed ID: 34976022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of N6-Methyladenosine Methylation Regulators in the Drug Therapy of Digestive System Tumours.
    Xia Z; Kong F; Wang K; Zhang X
    Front Pharmacol; 2022; 13():908079. PubMed ID: 35754499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of m6A Regulator-Mediated Methylation Modification Patterns and Tumor Microenvironment Infiltration in Ovarian Cancer.
    Luo Y; Sun X; Xiong J
    Front Cell Dev Biol; 2021; 9():794801. PubMed ID: 35087835
    [No Abstract]   [Full Text] [Related]  

  • 19. N6-Methyladenosine Regulator-Mediated Immue Patterns and Tumor Microenvironment Infiltration Characterization in Glioblastoma.
    Xiong W; Li C; Wan B; Zheng Z; Zhang Y; Wang S; Fan J
    Front Immunol; 2022; 13():819080. PubMed ID: 35359993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrative Analysis of m6A RNA Methylation Regulators and the Tumor Immune Microenvironment in Non-Small-Cell Lung Cancer.
    Zhu J; Jiang Y; Wang T; Wu A; Zhou T; Zhang A; Tang Y; Shen Z; Wang J; Zhou H; Shi J; Chen J
    Dis Markers; 2022; 2022():2989200. PubMed ID: 35186164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.